Skip to content

Dose Exploration of Liposomal Bupivacaine Injection Combined with Bupivacaine for Postoperative Analgesia in Elderly Patients Undergoing Total Knee Arthroplasty

Dose Exploration of Liposomal Bupivacaine Injection Combined with Bupivacaine for Postoperative Analgesia in Elderly Patients Undergoing Total Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126498
Enrollment
Unknown
Registered
2026-06-10
Start date
2026-06-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Experimental Group:Ultrasound-guided adductor canal block with 5 mL mixture containing 0.665% liposomal bupivacaine (LB) plus 0.2% bupivacaine, with adaptive volume adjustment: the initial injection v
in the event of block failure, the volume is increased by 2 mL.

Sponsors

Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 60 and 80 years old; 2. Scheduled to undergo unilateral total knee arthroplasty (TKA) under general anesthesia; 3. Patients classified as American Society of Anesthesiologists (ASA) physical status I to III; 4. Body Mass Index (BMI) ranging from 18 to 25 kg/m².

Exclusion criteria

Exclusion criteria: 1. Patients who have a history of contralateral total knee arthroplasty within the past year or are scheduled for bilateral total knee arthroplasty; 2. Patients with infection, deformity at the adductor canal or femoral nerve puncture site of the affected limb on the ipsilateral side, or combined with other neurological disorders; 3. Patients with preoperative mental illnesses, cognitive dysfunction, language disorders or other conditions that result in impaired communication ability; 4. Patients with diseases requiring chronic analgesic treatment or opioid addiction; 5. Patients with significant preoperative abnormalities in liver and renal function, electrolytes and coagulation function, active or recurrent peptic ulcers, gastrointestinal bleeding or coronary heart disease; 6. Patients with allergy, hypersensitivity, intolerance or contraindications to medications used during the perioperative period; 7. Secondary surgery or emergency surgery cases; 8. Any other patients deemed ineligible for participation in this study by the investigators.

Design outcomes

Primary

MeasureTime frame
Resting pain score (NRS) and effective compression times of patient-controlled analgesia (PCA) pump;

Countries

China

Contacts

Public ContactWenping Liu

Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine

a18031783173@163.com+86 180 3178 3173

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026